02696 HENLIUS
- 16.460
- -0.320-1.91%
HENLIUS News
Henlius Trastuzumab Receives FDA Approval in the United States
Henlius Biotech, Inc. (2696.HK) announced that the company's business partner, Accord BioPharma Inc. (the U.S. specialty division of Intas...
Fuhong Hanlin (02696) achieved revenue of about 1,349 billion yuan in the first quarter
Zhitong Finance App News, Fu Hong Han Lin (02696) announced that in the first quarter of 2024, the Group will seize its existing first-mover advantage, comprehensively promote the product commercialization process, and continue to build innovative business models and optimize resource allocation. During the reporting period, the Group achieved revenue of approximately RMB 1,349 billion. The results of the two core products sold and promoted in China (excluding Hong Kong, Macao and Taiwan regions, same below) led by the Group's self-built commercial team during the reporting period are as follows: Han Quyou (trastuzumab for injection, European trade name: Zercepac, US product name: HERCESSITM,
Shanghai Henlius Biotech's Cancer Drug Gets the Nod From US FDA
The US Food and Drug Administration (FDA) approved Shanghai Henlius Biotech's (HKG:2696) drug HLX02 (trastuzumab for injection) for the treatment of multiple cancers, according to a Friday Hong Kong b
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China
Shanghai Henlius Biotech (HKG:2696) has dosed the first subject in a phase I clinical study of HLX6018 in healthy subjects in mainland China, a Tuesday filing on the Hong Kong bourse stated. HLX6018 i
Fu Hong Han Lin (02696): The phase 1 clinical study of HLX6018 in healthy subjects completed the first patient administration in China
Fu Hong Han Lin (02696) announced that recently, HLX6018 (recombinant anti-GARP/TGF-beta1...
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug
Shanghai Henlius Biotech's (HKG:2696) clinical trial application for HLX53 has been approved by the National Medical Products Administration of China, a Wednesday filing on the Hong Kong bourse said.
Fu Hong Han Lin (02696.HK): A clinical trial application for HLX53 combined with Hans-type and Hanbeitai for first-line treatment of locally advanced or metastatic hepatocellular carcinoma was approved by the State Drug Administration
Gelonghui, April 17, 丨 Fu Hong Han Lin (02696.HK) issued an announcement. Recently, the clinical trial application for HLX53 (anti-Tigit FC fusion protein) (“HLX53”) combined with Hans form (sululimab injection) (“Hans form”) and Hanbetai (bevacizumab injection) (“Hanbetai”) for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC) was approved by the National Drug Administration (“NMPA”). The company plans to be in China after the conditions are met (excluding Hong Kong, Macao and Taiwan regions,
Fosun Pharmaceuticals (600196.SH): Holding subsidiary approved for drug clinical trials
Gelonghui, April 17 | Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary recently received approval from the National Drug Administration to conduct clinical trials with HLX53 (i.e. anti-Tigit FC fusion protein) combined with Hans form (i.e. slulizumab injection) and Hanbetai (i.e. bevacizumab injection) for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC). Fu Hong Hanlin plans to launch phase II of this treatment plan in China (excluding Hong Kong, Macao and Taiwan regions) when conditions are met
復宏漢霖：2023 年度報告
Fosun Pharmaceutical (02196): Fuhong Hanlin plans to guarantee Hanlin Pharmaceuticals's financing debt with a principal amount not exceeding 150 million yuan from China Construction Bank
Fosun Pharmaceutical (02196) issued an announcement. On April 9, 2024, the company's holding subsidiary Shanghai Fuhong Hanlin Biotech...
Can Shanghai Henlius Biotech, Inc.'s (HKG:2696) ROE Continue To Surpass The Industry Average?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). We'll use ROE to
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint
Shanghai Henlius Biotech and Organon (OGN) said Monday that the phase 3 study for the investigational Prolia and Xgeva (denosumab) biosimilar HLX14 met the primary endpoints. The study aimed to compar
Phase 3 Trial of Shanghai Henlius Biotech's Osteoporosis Drug Meets Primary Study Endpoints
A phase 3 clinical study of Shanghai Henlius Biotech's (HKG:2696) HLX14 for the treatment of osteoporosis in postmenopausal women at high risk for fracture has met the primary study endpoints, a Frida
Fu Hong Han Lin (02696.HK): An international multicenter phase 3 clinical study of desumab biosimilar drug HLX14 (recombinant anti-RANKL whole-human monoclonal antibody injection) for the treatment of osteoporosis in postmenopausal women with a high risk
Gelonghui, April 5, 丨 Fu Hong Han Lin (02696.HK) announced that recently, an international multicenter phase 3 clinical study of the desumab biosimilar drug HLX14 (recombinant anti-RANKL whole human monoclonal antibody injection) (HLX14) independently developed by the company to treat osteoporosis in postmenopausal women with a high risk of fractures reached the main research end. This study is a randomized, double-blind, international multicenter, parallel-controlled phase 3 clinical trial to compare HLX14 with original desulumab (Prolia) in postmenopausal female subjects with high risk of fractures
Shanghai Henlius Biotech Turns to Profit in 2023
Shanghai Henlius Biotech (HKG:2696) booked a profit attributable to owners of the company of 546 million yuan in 2023, recovering from an attributable loss of 695.3 million yuan in 2022, according to
Fu Hong Han Lin (02696): Achieving full year profit for the first time, the “flywheel effect” is highlighted under systematic competitive advantage
With the introduction of policies and measures and continuous optimization of resource allocation, the domestic biomedical industry is entering a critical stage of comprehensive development. Recently, a policy document on “full chain support for innovative drugs” came out of the market, lighting a beacon of guidance for innovative pharmaceutical companies at the crossroads of development. This is certainly a huge benefit for Fu Hong Hanlin (02696), who achieved full year profits for the first time and successfully completed the transformation to an international Biopharma. According to the newly released 2023 annual report, it relies on global R&D, overseas registration, quality control, and marketing under the guidance of “internal and external training” strategy
Press Release: Henlius 2023 Annual Results: Revenue Surpassed RMB5.39 Billion With a Net Profit RMB546 Million, First Full-year Profitability Achieved
Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved PR Newswire SHANGHAI, March 21, 2024 SHANGHAI, March 21, 2024
Fu Hong Han Lin (02696) continues to push for global approval of pipeline products to achieve net profit of 546 million yuan in 2023, turning a year-on-year loss into profit
According to the Zhitong Finance App, Fu Hong Hanlin (02696) announced its 2023 results, with total revenue of about RMB 5.395 billion (same unit), an increase of about 67.8% over the previous year. Gross profit of about $3,919 million, up 65.34% year on year; net profit of $546 million, net loss of about $695 million in 2022; basic profit per share of 1.01 yuan. During the reporting period, Han Quyou achieved sales revenue of about 2,644 billion yuan, an increase of 56.1% over the previous year, and maintained rapid growth. Hans achieved sales revenue of about 1.12 billion yuan, an increase of 230.2% over the previous year, and the growth trend was rapid. Hanbei
HENLIUS: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Henlius Biotech Doses First Patient in Phase 1 Clinical Trial of Cancer Drug
Shanghai Henlius Biotech (HKG:2696) said the phase 1 clinical study of HLX42 is underway and the first dose was administered to a patient recently, according to a Thursday Hong Kong bourse filing. The
Analysis
Price Target
No Data
